Key facts
- ReproNovo’s last known valuation is $174.4M (May 2025).
- It has raised $65.0M; the latest was Early Stage VC ($65.0M) in May 2025.
- Notable investors include M Ventures, ALSA Ventures, AXA IM Alts, Jeito, Ysios Capital.
- Status: Privately Held (backing).
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for ReproNovo
- ·The full record, as it builds
Funding rounds
No funding rounds for ReproNovo are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About ReproNovo
Operator of a health and reproductive medicine firm intended to develop and bring new treatments to patients. The company offers scientific expertise in designing and conducting clinical trials, development of orally administered therapeutic candidates for male and female infertility and uterine health, enabling healthcare providers and patients affected by fertility challenges to access emerging treatment options that aim to improve clinical outcomes.
- Sector
- Healthcare
- HQ
- Lausanne, Switzerland
- Founded
- 2021
- Employees
- 20
- Website
- repronovo.com/
- Ownership
- Privately Held (backing)
ReproNovo doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in ReproNovo shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on ReproNovo in its N-PORT filings yet. We sweep new filings monthly.